Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells

Abstract Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit ligand-specific transcriptional programs in breast cancer...

Full description

Bibliographic Details
Main Authors: G. R. Hancock, K. S. Young, D. J. Hosfield, C. Joiner, E. A. Sullivan, Y. Yildiz, M. Lainé, G. L. Greene, S. W. Fanning
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00497-9
_version_ 1827775134358831104
author G. R. Hancock
K. S. Young
D. J. Hosfield
C. Joiner
E. A. Sullivan
Y. Yildiz
M. Lainé
G. L. Greene
S. W. Fanning
author_facet G. R. Hancock
K. S. Young
D. J. Hosfield
C. Joiner
E. A. Sullivan
Y. Yildiz
M. Lainé
G. L. Greene
S. W. Fanning
author_sort G. R. Hancock
collection DOAJ
description Abstract Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit ligand-specific transcriptional programs in breast cancer and other hormone-responsive tissues. By affecting disparate ligand binding domain structural features, unconventional ligand scaffolds can redirect ERα genomic binding patterns to engage novel therapeutic transcriptional programs. To improve our understanding of these ERα structure-transcriptional relationships, we develop a series of chemically unconventional antagonists based on the antiestrogens elacestrant and lasofoxifene. High-resolution x-ray co-crystal structures show that these molecules affect both classical and unique structural motifs within the ERα ligand binding pocket. They show moderately reduced antagonistic potencies on ERα genomic activities but are effective anti-proliferative agents in luminal breast cancer cells. Interestingly, they favor a 4-hydroxytamoxifen-like accumulation of ERα in breast cancer cells but lack uterotrophic activities in an endometrial cell line. Importantly, RNA sequencing shows that the lead molecules engage transcriptional pathways similar to the selective estrogen receptor degrader fulvestrant. This advance shows that fulvestrant-like genomic activities can be achieved without affecting ERα accumulation in breast cancer cells.
first_indexed 2024-03-11T13:47:45Z
format Article
id doaj.art-e634006f12244e7a85928336ed7747d2
institution Directory Open Access Journal
issn 2374-4677
language English
last_indexed 2024-03-11T13:47:45Z
publishDate 2022-12-01
publisher Nature Portfolio
record_format Article
series npj Breast Cancer
spelling doaj.art-e634006f12244e7a85928336ed7747d22023-11-02T10:12:02ZengNature Portfolionpj Breast Cancer2374-46772022-12-018112610.1038/s41523-022-00497-9Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cellsG. R. Hancock0K. S. Young1D. J. Hosfield2C. Joiner3E. A. Sullivan4Y. Yildiz5M. Lainé6G. L. Greene7S. W. Fanning8Department of Cancer Biology, Loyola University Chicago, Stritch School of MedicineDepartment of Cancer Biology, Loyola University Chicago, Stritch School of MedicineBen May Department for Cancer Research, University of ChicagoDepartment of Cancer Biology, Loyola University Chicago, Stritch School of MedicineDepartment of Cancer Biology, Loyola University Chicago, Stritch School of MedicineDepartment of Cancer Biology, Loyola University Chicago, Stritch School of MedicineBen May Department for Cancer Research, University of ChicagoBen May Department for Cancer Research, University of ChicagoDepartment of Cancer Biology, Loyola University Chicago, Stritch School of MedicineAbstract Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit ligand-specific transcriptional programs in breast cancer and other hormone-responsive tissues. By affecting disparate ligand binding domain structural features, unconventional ligand scaffolds can redirect ERα genomic binding patterns to engage novel therapeutic transcriptional programs. To improve our understanding of these ERα structure-transcriptional relationships, we develop a series of chemically unconventional antagonists based on the antiestrogens elacestrant and lasofoxifene. High-resolution x-ray co-crystal structures show that these molecules affect both classical and unique structural motifs within the ERα ligand binding pocket. They show moderately reduced antagonistic potencies on ERα genomic activities but are effective anti-proliferative agents in luminal breast cancer cells. Interestingly, they favor a 4-hydroxytamoxifen-like accumulation of ERα in breast cancer cells but lack uterotrophic activities in an endometrial cell line. Importantly, RNA sequencing shows that the lead molecules engage transcriptional pathways similar to the selective estrogen receptor degrader fulvestrant. This advance shows that fulvestrant-like genomic activities can be achieved without affecting ERα accumulation in breast cancer cells.https://doi.org/10.1038/s41523-022-00497-9
spellingShingle G. R. Hancock
K. S. Young
D. J. Hosfield
C. Joiner
E. A. Sullivan
Y. Yildiz
M. Lainé
G. L. Greene
S. W. Fanning
Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
npj Breast Cancer
title Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
title_full Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
title_fullStr Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
title_full_unstemmed Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
title_short Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
title_sort unconventional isoquinoline based serms elicit fulvestrant like transcriptional programs in er breast cancer cells
url https://doi.org/10.1038/s41523-022-00497-9
work_keys_str_mv AT grhancock unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT ksyoung unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT djhosfield unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT cjoiner unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT easullivan unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT yyildiz unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT mlaine unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT glgreene unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells
AT swfanning unconventionalisoquinolinebasedsermselicitfulvestrantliketranscriptionalprogramsinerbreastcancercells